Eleni Kampylafka

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

CD200+ fibroblasts form a pro-resolving mesenchymal network in arthritis.

CD200+ fibroblasts form a pro-resolving mesenchymal network in arthritis.

Journal: Nature immunology

Published: March 15, 2023

Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis.

Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis.

Journal: Rheumatology (Oxford, England)

Published: August 06, 2022

Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial.

Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial.

Journal: Arthritis research & therapy

Published: January 14, 2021

Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.

Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.

Journal: Arthritis research & therapy

Published: June 15, 2020

Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis.

Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 03, 2019

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.

Journal: Arthritis research & therapy

Published: March 22, 2019

Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.

Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.

Journal: Arthritis research & therapy

Published: March 06, 2019

Erdheim-Chester disease : An important differential diagnosis and its main symptoms

Erdheim-Chester disease : An important differential diagnosis and its main symptoms

Journal: Zeitschrift fur Rheumatologie

Published: November 16, 2018

Novel molecular mechanisms in the pathophysiology of psoriatic arthritis

Novel molecular mechanisms in the pathophysiology of psoriatic arthritis

Journal: Zeitschrift fur Rheumatologie

Published: July 14, 2018

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.

Journal: Arthritis research & therapy

Published: April 09, 2018

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Journal: Seminars in arthritis and rheumatism

Published: March 05, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026